Home › Blood Cancers › NCT05646576
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy: The PEACE Study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 18 years or older. * Ability to complete surveys in English or with assistance of an interpreter. * Diagnosis of a hematologic malignancy. * Receiving autologous adoptive cellular therapy (ACT) at MGH with an FDA approved cellular therapy product. Exclusion Criteria: * Impaired cognition or uncontrolled mental illness that prohibits study compliance based on the oncology clinician assessment. * Already receiving palliative care (PC).
About the study
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups.
The names of the study intervention groups involved in this study are:
* Palliative care (PEACE) plus usual oncology care * Usual care (standard oncology care)
Participation in this research study is expected to last for up to 2 years.
It is expected that about 90 people will take part in this research study.
What is being tested
- Palliative Care (behavioral)
- Usual Care (behavioral)
Sponsor: Massachusetts General Hospital · Participants: 90 · Started: Dec 30, 2022
Contact the study team
- Patrick C Johnson · Phone: 617-724-4000
Official record on ClinicalTrials.gov — NCT05646576
Locations in the U.S.
| Massachusetts | Massachusetts General Hospital Cancer Center, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.